Hypoxia and anemia: Factors in decreased sensitivity to radiation therapy and chemotherapy?

Oncologist

Volumn 9, Issue SUPPL. 5, 2004, Pages 31-40

  Harrison, Louis ^a   Blackwell, Kimberly ^b  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anemia; Chemotherapy; Epoetin alfa; Hemoglobin; Hypoxia; Outcomes; Radiotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN SULFATE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; OXYGEN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONFERENCE PAPER; DRUG EFFICACY; HEAD AND NECK CARCINOMA; HUMAN; HYPOXIA; LYMPH NODE METASTASIS; OXYGEN TENSION; OXYGENATION; PRIORITY JOURNAL; RECURRENT DISEASE; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA;

ANEMIA; CELL HYPOXIA; COMBINED MODALITY THERAPY; DRUG RESISTANCE, NEOPLASM; ERYTHROPOIETIN; FEMALE; HEAD AND NECK NEOPLASMS; HEMOGLOBINS; HUMANS; RADIATION TOLERANCE; SARCOMA; UTERINE CERVICAL NEOPLASMS;

EID: 10644283057     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.9-90005-31     Document Type: Conference Paper

References (76)

1. Vaupel P, Briest S, Höckel M. Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wein Med Wochenschr 2002;152:334-342.
2. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001;18:243-259.
3. Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31-39.
4. Brizel DM, Sibley GS, Prosnitz LR et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-289.
5. Vaupel P. Blood flow and oxygenation status of head and neck carcinomas. Adv Exp Med Biol 1997;428:89-95.
6. Vaupel P. Durchblutung und oxygenierungsstatus von kopfhals-tumoren. In: Böttcher HD, Wendt TG, Henke M, eds. Klinik des Rezidivtumors im Kopf-Hals-Bereich. Grundlagen-Diagnostik-Therapie. München, Germany: Zuckschwerdt, 2001:7-23.
7. Kallinowski F, Buhr HJ. Tissue oxygenation of primary, metastatic and xenografted rectal cancers. In: Vaupel P, Kelleher DK, Günderoth M, eds. Tumor Oxygenation. Stuttgart, Germany: Fischer, 1995:205-209.
8. Mattern J, Kallinowski F, Herfarth C et al. Association of resistance-related protein expression with poor vascularization and low levels of oxygen in human rectal cancer. Int J Cancer 1996;67:20-23.
9. Movsas B, Chapman JD, Greenberg RE et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 2000;89:2018-2024.
10. Movsas B, Chapman JD, Horwitz EM et al. Hypoxic regions exist in human prostate carcinoma. Urology 1999;53:11-18.
11. Koong AC, Denko NC, Hudson KM et al. Candidate genes for the hypoxic tumor phenotype. Cancer Res 2000;60:883-887.
12. 2 distribution and bioreductive enzymes in human malignant brain tumors. Int J Radiat Oncol Biol Phys 1994;29:427-431.
13. Collingridge DR, Piepmeier JM, Rockwell S et al. Polarographic measurements of oxygen tension in human glioma and surrounding peritumoural brain tissue. Radiother Oncol 1999;53:127-131.
14. Brizel DM, Scully SP, Harrelson JM et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-943.
15. Nordsmark M, Hoyer M, Keller J et al. The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. Int J Radiat Oncol Biol Phys 1996;35:701-708.
16. Lartigau E, Randrianarivelo H, Avril MF et al. Intratumoral oxygen tension in metastatic melanoma. Melanoma Res 1997;7:400-406.
17. Vaupel P, Höckel M. Tumor hypoxia and therapeutic resistance. In: Nowrousian MR, ed. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Berlin. Heidelberg, New York: Springer, 2002:127-146.
18. Teicher BA. Physiologic mechanisms of therapeutic resistance. Blood flow and hypoxia. Hematol Oncol Clin North Am 1995;9:475-506.
19. Vaupel P. The role of hypoxia-induced factors in tumor progression. The Oncologist 2004;9(suppl 5):10-17.
20. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. The Oncologist 2004;9(suppl 5):4-9.
21. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
22. Höckel M, Schienger K, Höckel S et al. Association between tumor hypoxia and malignant progression: the clinical evidence in cancer of the uterine cervix. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia. Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Germany: Wissenschaftl Verlagsgesellschaft, 1999:65-74.
23. Mundt AJ, Connell PP, Campbell T et al. Race and clinical outcome in patients with carcinoma of the uterine cervix treated with radiation therapy. Gynecol Oncol 1998;71:151-158.
24. Takeshi K, Katsuyuki K, Yoshiaki T et al. Definitive radiotherapy combined with high-dose-rate brachytherapy for Stage III carcinoma of the uterine cervix: retrospective analysis of prognostic factors concerning patient characteristics and treatment parameters. Int J Radiat Oncol Biol Phys 1998;41:319-327.
25. Harrison LB, Chadha M, Hill RJ et al. Impact of tumor hypoxia and anemia on radiation therapy outcomes. The Oncologist 2002;7:492-508.
26. Hall EJ. Radiobiology for the Radiologist. Philadelphia, PA: Lippincott, 1994.
27. Molls M, Stadler P, Becker A et al. Relevance of oxygen in radiation oncology. Mechanisms of action, correlation to low hemoglobin levels. Strahlenther Onkol 1998;174(suppl 4):13-16.
28. Kumar P. Impact of anemia in patients with head and neck cancer. The Oncologist 2000;5(suppl 2):13-18.
29. Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93:266-276.
30. Garrido C, Gurbuxani S, Ravagnan L et al. Heat shock proteins: endogenous modulators of apoptotic cell death. Biochem Biophys Res Commun 2001;286:433-442.
31. Nylandsted J, Rohde M, Brand K et al. Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2. Proc Natl Acad Sci USA 2000;97:7871-7876.
32. Jaattela M, Wissing D, Kokholm K et al. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteases. EMBO J 1998;17:6124-6134.
33. Ciocca DR, Clark GM, Tandon AK et al. Heat shock protein hsp70 in patients with axillary lymph node-negative breast cancer: prognostic implications. J Natl Cancer Inst 1993;85:570-574.
34. Lazaris ACh, Chatzigianni EB, Panoussopoulos D et al. Proliferating cell nuclear antigen and heat shock protein 70 immunolocalization in invasive ductal breast cancer not otherwise specified. Breast Cancer Res Treat 1997;43:43-51.
35. Vargas-Roig LM, Fanelli MA, Lopez LA et al. Heat shock proteins and cell proliferation in human breast cancer biopsy samples. Cancer Detect Prev 1997;21:441-451.
36. Vargas-Roig LM, Gago FE, Tello O et al. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79:468-475.
37. Gatenby RA, Kessler HB, Rosenblum JS et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int J Radiat Oncol Biol Phys 1988;14:831-838.
38. Brizel DM, Dodge RK, Clough RW et al. Oxygenation of head and neck cancer: Changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-117.
39. Rudat V, Vanselow B, Wollensack P et al. Repeatability and prognostic impact of the pretreatment pO(2) histography in patients with advanced head and neck cancer. Radiother Oncol 2000;57:31-37.
40. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
41. Höckel M, Vorndran B, Schlenger K et al. Tumor oxygenation: a new predictive parameter in locally advanced cancer of the uterine cervix. Gynecol Oncol 1993;51:141-149.
42. Fyles AW, Milosevic M, Wong R et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998;48:149-156.
43. Sundfor K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br J Cancer 1998;78:822-827.
44. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104.
45. Sundfor K, Lyng H, Trope CG et al. Treatment outcome in advanced squamous cell carcinoma of the uterine cervix: relationships to pretreatment tumor oxygenation and vascularization. Radiother Oncol 2000;54:101-107.
46. Höckel M, Schlenger K, Aral B et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-4515.
47. Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol 2001;28(suppl 8):36-41.
48. 2 during early radiotherapy in cervical cancers: improved local control in primarily hypoxic tumors with " reoxygenation" and the impact of hemoglobin. Int J Radiat Oncol Biol Phys 1999;45(suppl 1):364.
49. Durand RE. Intermittent blood flow in solid tumours - an under-appreciated source of 'drug resistance'. Cancer Metastasis Rev 2001;20:57-61.
50. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81.
51. Teicher BA, Holden SA, al-Achi A et al. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSa11C murine fibrosarcoma. Cancer Res 1990;50:3339-3344.
52. Teicher BA. Hypoxia and drug resistance. Cancer Metastasis Rev 1994;13:139-168.
53. Sakata K, Kwok TT, Murphy BJ et al. Hypoxia-induced drug resistance: comparison to P-glycoprotein-associated drug resistance. Br J Cancer 1991;64:809-814.
54. Hickman JA, Potten CS, Merritt AJ et al. Apoptosis and cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci 1994;345:319-325.
55. Littlewood TJ. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol 2001;28(suppl 8):49-53.
56. Becker A, Hänsgen G, Bloching M et al. Oxygenation of squamous cell carcinoma of the head and neck: comparison of primary tumors, neck node metastases, and normal tissue. Int J Radiat Oncol Biol Phys 1998;42:35-41.
57. Stadler P, Becker A, Feldmann H et al. The hypoxic subvolume influences the prognosis of head and neck cancer. Int J Radiat Oncol Biol Phys 1998;42:147.
58. Vaupel P, Mayer A, Briest S et al. Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003;63:7634-7637.
59. Vaupel P, Thews O, Mayer A et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-731.
60. Rockwell S, Keyes SR, Sartorelli AC. Modulation of the anti-neoplastic efficacy of mitomycin C by dicoumarol in vivo. Cancer Chemother Pharmacol 1989;24:349-353.
61. Obralic N, Bilenjki D, Bilbija Z. Prognostic importance of anemia related parameters in patients with carcinoma of the cervix uteri. Acta Oncol 1990;29:199-201.
62. Warde P, O'Sullivan B, Bristow RG et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41:347-353.
63. Overgaard J, Hansen HS, Overgaard M et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998;46:135-146.
64. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol 1996;6:10-21.
65. Silver DF, Piver MS. Effects of recombinant human erythropoietin on the antitumor effect of cisplatin in SCID mice bearing human ovarian cancer: a possible oxygen effect. Gynecol Oncol 1999;73:280-284.
66. Thews O, Kelleher DK, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-1361.
67. Degner FL, Sutherland RM. Mathematical modelling of oxygen supply and oxygenation in tumor tissues: prognostic, therapeutic, and experimental implications. Int J Radiat Oncol Biol Phys 1988;15:391-397.
68. Thews O, Koenig R, Kelleher DK et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
69. Kelleher DK, Thews O, Vaupel P. Modulation of tumor oxygenation and radiosensitivity to erythropoietin. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia, Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Germany: Wissenschaftl Verlagsgesellschaft, 1999:39-46.
70. Stüben G, Pöttgen C, Knuhmann K et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358-1362.
71. Stüben G, Thews O, Pöttgen C et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-625.
72. Stüben G, Thews O, Pottgen C et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-350.
73. Henke M, Guttenberger R, Barke A et al. Erythropoietin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999;50:185-190.
74. Lavey RS. Clinical trial experience using erythropoietin during radiation therapy. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia. Pathophysiology, Clinical Significance and Therapeutic Perspectives. Stuttgart, Germany: Wissenschaftl Verlagsgesellschaft, 1999:99-105.
75. Henke M, Sindlinger F, Ikenberg H et al. Blood hemoglobin level and treatment outcome of early breast cancer. Strahlenther Onkol 2004;180:45-51.
76. Glaser CM, Millesi W, Kornek GV et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-715.